Jazz Pharmaceuticals PLC (JAZZ) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.

Total Revenue Chart for Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC (JAZZ) revenue for FY2025 was USD 4.3B, a 4.9% change from FY2024. Jazz Pharmaceuticals PLC's revenue grew from USD 21.4M in 2005 to USD 4.3B in 2025 (19802.9% over 20 years). Earnings per share grew from USD 0.83 in 2010 to USD -3.58 in 2022 (-530.8%). Revenue compound annual growth rate: 5-year CAGR of 12.5%, 10-year CAGR of 12.4%, 20-year CAGR of 30.3%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$15.02B
Implied Share Price
$231.39
Enterprise Value
$17.47B
Revenue (TTM)
$4.60B
EBITDA
$1.93B
Profit Margin
20.45%
Trailing P/E
16.18
Forward P/E
10.89
Price/Book (MRQ)
3.25
Price/Sales (TTM)
3.26
EV/EBITDA
11.03
EV/Revenue
3.88
Dividend Yield
—
Book Value
$74.10
Free Cash Flow (FY2025)
$1.15B
Free Cash Flow Yield
7.63%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.